[1] Feng R, Su Q, Huang X, et al. Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? Cancer Commun (Lond),2023,43(1):75-86. [2] Chang MH. Prevention of hepatitis B virus infection and liver cancer. Recent Results Cancer Res,2021,217(1):71-90. [3] 莫春明,黄德佳,韦惠章,等. TACE术治疗的原发性肝癌患者血清IL-33水平变化及其对发热的鉴别意义探讨. 实用肝脏病杂志, 2023, 26(6): 887-890. [4] Peisen F, Maurer M, Grosse U, et al. Intraprocedural cone-beam CT with parenchymal blood volume assessment for transarterial chemoembolization guidance: Impact on the effectiveness of the individual TACE sessions compared to DSA guidance alone. Eur J Radiol, 2021, 140:109768. [5] Sun Z, Shi Z, Xin Y, et al. Contrast-enhanced CT imaging features combined with clinical factors to predict the efficacy and prognosis for transarterial chemoembolization of hepatocellular carcinoma. Acad Radiol,2023,76(22):687-690. [6] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版) . 中华肝脏病杂志,2020,28(2):112-128. [7] Majeed NF, Ali SM, Therrien J,et al. Virtual monoenergetic spectral detector CT for preoperative CT angiography in liver donors. Curr Probl Diagn Radiol, 2022, 51(4):517-523. [8] Zhong H, Huang Q, Zheng X,et al. Generation of virtual monoenergetic images at 40 keV of the upper abdomen and image quality evaluation based on generative adversarial networks. BMC Med Imaging. 2024, 24(1):151. [9] Guo L, Wei X, Feng S, et al. Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial. Hepatol Int,2022,16(6):1368-1378. [10] Ding X, Sun W, Li W, et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. Cancer,2021,127(20):3782-3793. [11] Yus TM, Sarastika HY, Soeprijanto B. Feeding artery characteristics and enhancement patterns of hepatoblastoma patients treated with transarterial chemoembolization (TACE): Digital subtraction angiography evaluation. Narra J, 2023, 3(3):e209. [12] 魏博文,任峥,张亮,等. 增强CT扫描评估TACE术治疗的原发性肝癌患者效果分析. 实用肝脏病杂志,2022,25(4):603-604. [13] Maraia D, Hemmerdinger S, Chiarolanzio P, et al. Dual-layer spectral CT virtual-non-contrast images aid in parathyroid adenoma analysis and radiation dose reduction: confirmation of findings from dual-energy CT. Clin Imaging, 2022, 84:113-117. [14] Bucolo GM, Ascenti V, Barbera S,et al. Virtual non-contrast spectral CT in renal masses: Is it time to discard conventional unenhanced phase? J Clin Med,2023, 12(14):4718. [15] Yan M, Liu Y, You H,et al. Differentiation of small gastrointestinal stromal tumor and gastric leiomyoma with contrast-enhanced CT. J Healthc Eng, 2023:6423617. [16] Li W, Lu M, Yuan G,et al. Comparison of the efficacy and safety of TACE-HAIC-MTTs-ICIs and TACE-MTTs-ICIs in the hepatocellular carcinoma: a prognostic analysis based on the dynamic changes of serum AFP. Int J Surg, 2025[online ahead of print]. [17] Kuo LF, Liu WC, Li MF,et al. Prognostic evaluation of conversion therapy following hepatic arterial infusion chemotherapy or immunotherapy in patients with advanced or transarterial chemoembolization unsuitable intermediate-stage hepatocellular carcinoma: A retrospective cohort study. Oncology, 2025, 103(7):549-561. [18] Verstraeten S, Ansems J, Ommen WV, et al. Comparison of true non-contrast and virtual non-contrast images in the characterization of renal lesions using detector-based spectral CT. Br J Radiol, 2023, 96(1149):20220157. [19] Ma G, Han D, Dang S,et al. Replacing true unenhanced imaging in renal carcinoma with virtual unenhanced images in dual-energy spectral CT: a feasibility study. Clin Radiol, 2021, 76(1):81,e21-81. [20] 杨佳欣,杨紫郡,陈卫.双源CT双能量TNC技术图像质量与诊断肝细胞癌效能分析.实用肝脏病杂志,2024,27(6):915-918. |